Jul 3 |
Apollomics announces changes in executive leadership team
|
Jul 3 |
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
|
Jun 4 |
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
May 29 |
Apollomics Announces Presentation at the 2024 BIO International Convention
|
May 8 |
Apollomics Announces Private Placement Financing and Addition to Board of Directors
|
Apr 25 |
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
|
Apr 10 |
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Apr 2 |
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|